One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Sentinel Lymph Node Biopsy in Cutaneous Melanoma—Where Do We Stand?
Michael A. Marchetti, MD1; Edmund K. Bartlett, MD2
doi : 10.1001/jamadermatol.2021.3048
JAMA Dermatol. 2021;157(10):1159-1160
Clinical Evidence on “Watchful Waiting” in Basal Cell Carcinoma
Mackenzie R. Wehner, MD, MPhil1,2
doi : 10.1001/jamadermatol.2021.3019
JAMA Dermatol. 2021;157(10):1161-1162
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis
Lawrence F. Eichenfield, MD1; Carsten Flohr, PhD2; Robert Sidbury, MD3; Elaine Siegfried, MD4; Zsuzsanna Szalai, MD5; Ryszard Galus, MD6; Zhirong Yao, PhD7; Hidetoshi Takahashi, MD8; Sébastien Barbarot, PhD9; Claire Feeney, MD10; Fan Zhang, PhD11; Marco DiBonaventura, PhD12; Ricardo Rojo, MD11; Hernan Valdez, MD12; Gary Chan, PharmD11
doi : 10.1001/jamadermatol.2021.2830
JAMA Dermatol. 2021;157(10):1165-1173
Dupilumab subcutaneous injection is approved for treating moderate-to-severe atopic dermatitis (AD) in adolescents, but there has been too little research on an efficacious systemic oral treatment with a favorable benefit-risk profile for adolescents with moderate-to-severe AD.
Evaluation of Watchful Waiting and Tumor Behavior in Patients With Basal Cell Carcinoma
Marieke E. C. van Winden, MD, MSc1; Charlotte R. M. Hetterschijt, MD1; Ewald M. Bronkhorst, MSc, PhD2; Peter C. M. van de Kerkhof, MD, PhD1; Elke M. G. J. de Jong, MD, PhD1; Satish F. K. Lubeek, MD, PhD1
doi : 10.1001/jamadermatol.2021.3020
JAMA Dermatol. 2021;157(10):1174-1181
Few studies have examined watchful waiting (WW) in patients with basal cell carcinoma (BCC), although this approach might be suitable in patients who might not live long enough to benefit from treatment.
Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Khalaf Kridin, MD, PhD1,2; Marie-Charlotte Brüggen, MD, PhD3,4,5,6; Ser-Ling Chua, PhD6,7; Anette Bygum, DMSci6,8; Sarah Walsh, MB, BCh6,9; Mirjam C. Nägeli, MD3,4; Vesta Kucinskiene, MD, PhD6,10,11; Lars French, MD, PhD6,12,13; Florence Tétart, MD6,14,15; Biagio Didona, MD6,16; Brigitte Milpied, MD6,14,17; Annamari Ranki, MD, PhD6,18,19; Carmen Salavastru, MD, PhD6,20,21; Eva B?ezinová, MD, PhD6,22; Sapna Divani-Patel, MBBS, BSc7; Tine Lorentzen, MD8; Julie Loft Nagel, MD8; Skaidra Valiukeviciene, MD10,11; Viktorija Karpavi?i?t?, MD, PhD11; George-Sorin Tiplica, MD6,20,23; Eva Oppel, MD12; Anna Oschmann, MD12; Nicolas de Prost, MD, PhD14,24; Artem Vorobyev, MD1,6,25; Saskia Ingen-Housz-Oro, MD6,14,26,27
doi : 10.1001/jamadermatol.2021.3154
JAMA Dermatol. 2021;157(10):1182-1190
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe drug reactions associated with a high rate of mortality and morbidity. There is no consensus on the treatment strategy.
Patterns of Atopic Eczema Disease Activity From Birth Through Midlife in 2 British Birth Cohorts
Katrina Abuabara, MD, MA, MSCE1; Morgan Ye, MPH1; David J. Margolis, MD, PhD2; Charles E. McCulloch, PhD3; Amy R. Mulick, MSc4; Richard J. Silverwood, PhD5; Alice Sullivan, PhD5; Hywel C. Williams, DSc6; Sinéad M. Langan, PhD4
doi : 10.1001/jamadermatol.2021.2489
JAMA Dermatol. 2021;157(10):1191-1199
Atopic eczema is characterized by a heterogenous waxing and waning course, with variable age of onset and persistence of symptoms. Distinct patterns of disease activity such as early-onset/resolving and persistent disease have been identified throughout childhood; little is known about patterns into adulthood.
Association of Atopic Dermatitis and Mental Health Outcomes Across Childhood
Chloe Kern, BA1; Joy Wan, MD, MSCE2; Kaja Z. LeWinn, ScD3; Faustine D. Ramirez, MD4; Yong Lee, MD1; Charles E. McCulloch, PhD5; Sinéad M. Langan, MSc, PhD6; Katrina Abuabara, MD, MA, MSCE1,7
doi : 10.1001/jamadermatol.2021.2657
JAMA Dermatol. 2021;157(10):1200-1208
Research has highlighted associations between atopic dermatitis (AD) and mental health conditions in adults. However, literature on the development of mental health comorbidities in children is limited despite the large burden of pediatric AD worldwide.
Prevalence of Central Sensitization in Patients With Hidradenitis Suppurativa
Pim Aarts, MD1; Jessie J. Aitken, MD1; Kelsey R. van Straalen, MD, PhD1
doi : 10.1001/jamadermatol.2021.2918
JAMA Dermatol. 2021;157(10):1209-1212
Chronic pain is one of the most prominent symptoms of hidradenitis suppurativa (HS) and an independent domain in the core outcome set for HS. Previously, the chronic, recurrent, inflammatory nature of HS was hypothesized to induce central sensitization (CS; alteration and amplification of pain perception). However, evidence for this hypothesis is currently lacking.
Patient Quality of Life After Interpolated Flap Repair of Nasal Mohs Surgery Defects
Tess M. Lukowiak, BS1; Allison M. Perz, BS2; Surya A. Veerabagu, BA3; Michael P. Lee, MD4; Donald Neal, MD5; Leora Aizman, BS6; Christopher J. Miller, MD7; Nicholas Golda, MD8; John G. Albertini, MD9; Todd Holmes, MD10; Anna Bar, MD11; Justin Leitenberger, MD11; Ian A. Maher, MD12; Joseph F. Sobanko, MD7; David Chen, MD10; Sumaira Aasi, MD13; Adam Sutton, MD, MBA14; H. William Higgins II, MD, MBE7; Thuzar M. Shin, MD, PhD7; Christine Weinberger, MD10; Adam Mattox, DO12; Ashley Wysong, MD14; Jeremy R. Etzkorn, MD7,15
doi : 10.1001/jamadermatol.2021.3161
JAMA Dermatol. 2021;157(10):1213-1216
Single-center studies have shown that patients report better skin cancer–specific quality of life (QOL) after Mohs micrographic surgery (MMS), but it is unclear whether this improved QOL applies to patients after MMS and complex reconstruction in cosmetically sensitive areas.
Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients
Paul R. Massey, MD, MPH1; Chrysalyne D. Schmults, MD, MSCE1; Sara J. Li, BS1; Sarah T. Arron, MD, PhD2; Maryam M. Asgari, MD, MPH3,4; Jan Nico Bouwes Bavinck, MD, PhD5; Elizabeth Billingsley, MD6; Travis W. Blalock, MD7; Katie Blasdale, MBBS8; Bryan T. Carroll, MD, PhD9,10; John A. Carucci, MD, PhD11; Alvin H. Chong, MBBS, MMed12,13; Sean R. Christensen, MD, PhD14; Christina Lee Chung, MD15,16; Jennifer A. DeSimone, MD17; Emilie Ducroux, MD18; Begoña Escutia-Muñoz, MD, PhD19; Carla Ferrándiz-Pulido, MD, PhD20,21; Matthew C. Fox, MD22; Roel E. Genders, MD, PhD5; Alexandra Geusau, MD23; Petter Gjersvik, MD, PhD24,25; Allison M. Hanlon, MD, PhD26; Edit B. Olasz Harken, MD, PhD27; Günther F.L. Hofbauer, MD28; R. Samuel Hopkins, MD29; Justin J. Leitenberger, MD29; Manisha J. Loss, MD30; Veronique Del Marmol, MD, PhD31; José M. Mascaró Jr, MD32; Sarah A. Myers, MD33; Bichchau T. Nguyen, MD, MPH34,35; Walmar R. P. Oliveira, MD, PhD36; Clark C. Otley, MD37; Charlotte M. Proby, MA38; Em?ke Rácz, MD, PhD39; Veronica Ruiz-Salas, MD, PhD40; Faramarz H. Samie, MD, PhD41; Deniz Seçkin, MD42; Syed N. Shah, MBBS43; Thuzar M. Shin, MD, PhD44; Stephen P. Shumack, MBBS45; Seaver L. Soon, MD46; Thomas Stasko, MD47; Elisa Zavattaro, MD, PhD48; Nathalie C. Zeitouni, MD49,50; Fiona O’Reilly Zwald, MD51,52,53; Catherine A. Harwood, MBBS, PhD54,55; Anokhi Jambusaria-Pahlajani, MD, MSCE22
doi : 10.1001/jamadermatol.2021.3180
JAMA Dermatol. 2021;157(10):1219-1226
There is a paucity of evidence to guide physicians regarding prevention strategies for cutaneous squamous cell carcinoma (CSCC) in solid organ transplant recipients (SOTRs).
Primary Cutaneous Endometriosis Presenting as an Umbilical Nodule
Peter G. Bittar, MD1; Katherine T. Hrynewycz, MD1; Elizabeth A. Bryant, MD1
doi : 10.1001/jamadermatol.2021.2571
JAMA Dermatol. 2021;157(10):1227
Intertriginous Xanthomas—Pathognomonic Cutaneous Markers of Homozygous Familial Hypercholesterolemia
Abheek Sil, MBBS1; Dibyendu Bikash Bhanja, MD2; Surajit Kumar Biswas, MD1
doi : 10.1001/jamadermatol.2021.3060
JAMA Dermatol. 2021;157(10):1228
Indurated Plaques With Telangiectasias on the Lower Limbs
Claudia Sarró-Fuente, MD1; Javier Martín-Alcalde, MD1; José Luis López-Estebaranz, PhD1
doi : 10.1001/jamadermatol.2021.3051
JAMA Dermatol. 2021;157(10):1229-1230
Ichthyosiform Rashes and Joint Pain in a Boy
Hsuan Ning Wang, MD1,2,3; Chao-Yi Wu, MD, PhD3,4; Chun-Bing Chen, MD1,2,3,5,6,7,8,9,10
doi : 10.1001/jamadermatol.2021.3498
JAMA Dermatol. 2021;157(10):1231-1232
Patient-Reported Outcome Measures as Complementary Information to Clinician-Reported Outcome Measures in Patients With Psoriasis
John S. Barbieri, MD, MBA1; Joel M. Gelfand, MD, MSCE1,2
doi : 10.1001/jamadermatol.2021.3341
JAMA Dermatol. 2021;157(10):1236-1237
Postmarketing Cases of Enfortumab Vedotin–Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis
Michelle Nadeau Nguyen, PharmD, BCOP, BCPS1; Melissa Reyes, MD, MPH, DTMH1; S. Christopher Jones, PharmD, MS, MPH1
doi : 10.1001/jamadermatol.2021.3450
JAMA Dermatol. 2021;157(10):1237-1239
Out-of-Pocket Costs of Specialty Medications for Psoriasis and Psoriatic Arthritis Treatment in the Medicare Population
Sarah P. Pourali, BS1; Leonce Nshuti, MS2; Stacie B. Dusetzina, PhD2
doi : 10.1001/jamadermatol.2021.3616
JAMA Dermatol. 2021;157(10):1239-1241
Role of Eosinophils in Angiolymphoid Hyperplasia With Eosinophilia
Marlena Grünewald, MD1; Dora Stölzl, MD1; Ulrike Wehkamp, MD1; Michael Weichenthal, MD1; Merit Kaeding, MD1; Thomas Schwarz, MD1; Guido Heine, MD1
doi : 10.1001/jamadermatol.2021.2732
JAMA Dermatol. 2021;157(10):1241-1243
Epidermolysis Bullosa Pruriginosa Treated With Baricitinib
Xingyuan Jiang, MD1; Huijun Wang, PhD1; Mingyang Lee, MD, PhD1; Zhimiao Lin, MD1
doi : 10.1001/jamadermatol.2021.3174
JAMA Dermatol. 2021;157(10):1243-1244
An Abscess Is Not a Descriptive Term but an Entity With a Universally Accepted Definition—A Clarification on Semantics
Dan Lipsker, MD, PhD1,2
doi : 10.1001/jamadermatol.2021.3169
JAMA Dermatol. 2021;157(10):1244-1245
An Abscess Is Not a Descriptive Term but an Entity With a Universally Accepted Definition—A Clarification on Semantics—Reply
John W. Frew, MBBS, MMed, MSc1; Afsaneh Alavi, MD2; Joslyn S. Kirby, MD, MS, MEd3
doi : 10.1001/jamadermatol.2021.2495
JAMA Dermatol. 2021;157(10):1245-1246
Errors in Table 1, Figure 3, and Results
doi : 10.1001/jamadermatol.2021.4398
JAMA Dermatol. 2021;157(10):1246
Errors in Abstract and Results Section
doi : 10.1001/jamadermatol.2021.4420
JAMA Dermatol. 2021;157(10):1246
